Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Izrael - angleščina - Ministry of Health

j-c health care ltd - loperamide hydrochloride - capsules - loperamide hydrochloride 2 mg - antipropulsives - control and symptomatic relief of acute diarrhea in adults, adolescents and children aged 6 years and older.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - loperamide hydrochloride - tablets - 2mg milligram - antipropulsives

Irska - angleščina - HPRA (Health Products Regulatory Authority)

imbat limited - loperamide hydrochloride - orodispersible tablet - 2 milligram - loperamide

Irska - angleščina - HPRA (Health Products Regulatory Authority)

imbat limited - dimethicone; loperamide hydrochloride - tablet - 2 mg/125 milligram(s) - antipropulsives; loperamide

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - loperamide hydrochloride -

Irska - angleščina - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - loperamide hydrochloride - orodispersible tablet - antipropulsives; loperamide

Kanada - angleščina - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - loperamide hydrochloride - tablet - 2mg - loperamide hydrochloride 2mg - antidiarrhea agents

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

prime pharmaceutical sdn. bhd. - loperamide hydrochloride -